Neurizon Therapeutics' (ASX:NUZ) lead amyotrophic lateral sclerosis (ALS) drug candidate, NUZ-001, received orphan medicinal product designation from the European Medicines Agency, according to a Tuesday filing with the Australian bourse.
The designation offers benefits like reduced regulatory fees, free protocol assistance, and 10 years of market exclusivity in the European Union upon product approval, the filing said.
The company plans to expedite preparations for the phase 2/3 Healey ALS platform trial to facilitate the clinical validation of NUZ-001, according to the filing.
Neurizon Therapeutics' shares fell nearly 3% in afternoon trade Wednesday.
Price (AUD): $0.17, Change: $-0.01, Percent Change: -2.86%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.